AbstractBySubCategory

Measuring Value and Costs

Cost, Value, and Policy in Quality

2017 ASCO Quality Care Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
An evaluation of the breast cancer Well Follow-up Care Initiative using administrative databases: A new model of analysis. Nicole Mittmann

01

Costs of potentially preventable emergency department use during cancer treatment: A regional study. Laura Panattoni

02

Cost and survival analysis before and after implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer. Yichen Zhang

03

Identifying cancer quality measurement gaps in the Choosing Wisely Initiative. Kelsey Corrigan

07

Pharmaceutical assistance foundations in the financing of cancer care. Aaron Philip Mitchell

08

National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial carcinoma. Rudy Sam Suidan

09

A cost-utility analysis of sentinel lymph node mapping, selective lymphadenectomy, and routing lymphadenectomy in the management of low-risk endometrial cancer. Rudy Sam Suidan

10

Preparing for bundled payments in urology: Defining episodes, evaluating variations in care, and demonstrating improved value. Eila C. Skinner

11

Trends in survival and costs among U.S. patients with multiple myeloma. Eric Maiese

12

Understanding the financial impact of beyond use date in a publicly funded cancer system. Erin Redwood

13

Optimizing formulary decisions. Henry Jacob Conter

14

What are the health care costs for chronic lymphocytic leukemia? Matthew J. Matasar

15

Redesigning care to lower episode costs in bone marrow transplantation. Laura J. Johnston

16

Real-world palbociclib dosing patterns and potential wastage associated with dose modifications among post-menopausal women with HR-positive/HER2-negative metastatic breast cancer (mBC). Nanxin Li

17

Comparing patients with breast and prostate cancer in terms of their mental health comorbidities as predictors of cost and utilization. Harry Burke

18

Quantifying episode-based costs of care under the oncology care model: Analysis of Medicare beneficiaries in the UAB cancer community network. Courtney Williams

19

Total healthcare, treatment, and supportive care costs among metastatic pancreatic cancer (MPC) patients (pts) treated with either nab-paclitaxel/gemcitabine (nab-P+G) or FOLFIRINOX (FFX) in the first-line (1L) setting. Brian Ung

20

Estimating health care costs for advanced metastatic bladder cancer patients who are lost to follow-up: Applications of the Kaplan-Meier sampling average (KMSA). Binglin Yue

21

Funding model for stem cell transplant. Julia Monakova

22

Predictors of no-show among international patients with cancer: A 4-year analysis. Nizar Bhulani

23

Health utility scores (HUS) and health-related quality of life (HRQoL) in stage 4 lung cancer (S4LC) patients with brain metastases (BM). Vivian Tam

24

Health economic impact of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET). Tara Beth Sanft

25

Outpatient management of pediatric oncology patients with low-risk fever and neutropenia: Implementation of new clinical practice guideline at Texas Children's Hospital. Abhishek Amar Bavle

26

Supportive oncology and survivorship care: Initial impact of the Coleman Supportive Oncology Collaborative. Julia Rachel Trosman

27

Pancreatic cancer cost-of-care in inpatient setting. Dhruv Bansal

28

Development of cancer care episodes to measure costs for breast, colorectal, and non-small cell lung cancer. Catherine R. Fedorenko

29

Disease complexity and economic burden on patients with colon cancer in the SEER-Medicare population. Maria Alma Rodriguez

30

Toxicity of high-dose interferon for high-risk melanoma in Ontario: A population-based study of health services use. Timothy P. Hanna

31